Strategic Communication and Public Relations

Plant compound protects healthy cells from chemotherapy drugs

No. 16 | 07/04/2014 | by Zim/Küh

Chemotherapy drugs attack not only cancer cells but more generally rapidly dividing tissues. This can cause side effects ranging from hair loss to nausea to deadly infections. Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the plant compound rocaglamide protects healthy cells from the toxic effects of chemotherapy drugs. This discovery may help reduce the side effects of cancer therapies.

The compound rocaglamide is extracted from plants of the Aglaia species.Picture: Nguyễn Thanh Quang, Wikimedia Commons

Most chemotherapy drugs damage the DNA of dividing cells. These include not only cancer cells but also healthy cells such as blood, hair follicles, and cells of the mucous membranes of the stomach and gut. So far, researchers have identified only a few drugs that can directly prevent such adverse side effects on healthy tissues, but it has been unclear whether some of these drugs also protect cancer cells themselves from the effects of chemotherapy. This motivated Dr. Min Li-Weber and her team at the DKFZ to search for new compounds. "Rocaglamide was one of many plant substances that we examined," said study head Li-Weber. "This substance is extracted from herbs and has been used in Chinese medicine for many years as, for example, an anti-inflammatory agent."

To determine whether rocaglamide protects healthy cells from chemotherapy drugs, the researchers treated white blood cells from healthy donors with various chemotherapy drugs while adding various levels of rocaglamide. The result: "The more rocaglamide we used, the more white blood cells survived," reports Li-Weber. By contrast, the substance did not have any impact on the survival rate of the cancer cell lines used in the experiment.

How exactly does rocaglamide work? Could it somehow prevent DNA damage in healthy cells? To pursue these questions, the scientists compared the state of DNA in cells either with or without rocaglamide after adding a chemotherapy drug. "The damage was almost identical," says Michael Becker, first author of the publication. "This means on the one hand that rocaglamide does not directly prevent the effects of chemotherapy drugs. On the other hand, it also means that the compound itself does not cause any DNA damage."

In further tests, the scientists found that rocaglamide inhibits the production of the protein p53. This protein, which is also called a "guardian of the genome," is produced by cells that have undergone DNA damage. When p53 reaches a certain level, it induces "programmed cell death,” making sure that the defective cell dies. "Rocaglamide prevents healthy cells that have had contact with a chemotherapy drug from producing the p53 protein and thus from activating programmed cell death," Becker explains. "Since p53 is absent or defective in the cancer cells of about half of all cancer types, rocaglamide had no impact on the cancer cells in our tests." Patients suffering from tumors that do not produce p53 may therefore benefit from rocaglamide, because in these cases, the substance protects only the healthy cells from the effects of chemotherapy.

However, what are the consequences if cells with damaged DNA do not die promptly? Could they give rise to new cancer cells? "Numerous experiments in other labs have shown that inhibiting p53 for a short time does not cause the cancer risk to rise," Becker reports. “Our next step is to determine whether this also holds true for rocaglamide." Becker already has a hypothesis, which remains to be tested, that might explain why p53 inhibitors do not increase a person’s risk of developing cancer: "They might give cells more time to repair damage to their DNA."

Becker MS, Schmezer P, Breuer R, Haas SF, Essers MA, Krammer PH, Li-Weber M. (2014) The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression. Cell Death Dis. doi: 10.1038/cddis.2013.528

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS